Goldman Sachs Starts Centessa Pharmaceuticals (CNTA) at Buy

Goldman Sachs analyst Salveen Richter initiates coverage on Centessa Pharmaceuticals (NASDAQ: CNTA) with a Buy rating and a price target of $42.00.

The analyst comments "CNTA is an umbrella company reimagining the R&D model and leveraging asset centricity at scale (ten subsidiaries, each led by a team of subject matter experts, are under the management of a centralized team with oversight capabilities). Four clinical stage programs are underway: Ph3 lixivaptan in autosomal dominant polycystic kidney disease (ADPKD; $2.1bn peak global sales), Ph2 serpinPC in hemophilia A and B ($1.4bn peak global sales), Ph1 ZF874 in alpha-1 antitrypsin deficiency (A1AT; $5.5bn peak global sales), and Ph2-ready imgatuzumab in cutaneous small cell carcinoma (CSCC; $476mn peak global sales), all of which will have value driving catalysts in 2021. Data from the first three programs will provide clarity on differentiation of the clinical profile, and we note the other 12 programs from the pipeline offer optionality."

For an analyst ratings summary and ratings history on Centessa Pharmaceuticals click here. For more ratings news on Centessa Pharmaceuticals click here.

Shares of Centessa Pharmaceuticals closed at $24.76 yesterday.

You May Also Be Interested In

• Centessa Pharmaceuticals (CNTA) Announces $100 Million Proposed Public Offering of American Depositary Shares
• Spotify (SPOT) PT Raised to $345 at Macquarie
• Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares